Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …

Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

Background First-line durvalumab plus etoposide with either cisplatin or carboplatin
(platinum–etoposide) showed a significant improvement in overall survival versus platinum …

PURPOSE: IMpower133 (ClinicalTrials. gov identifier: NCT02763579), a randomized,
double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed …

Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of …

Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune
response associated with immunological memory, provided they display sufficient …

Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the …

Tumor microenvironment (TME) has been reported to exhibit a crucial effect in lung cancer.
Therefore, this study was aimed to investigate the genes associated with TME and develop a …

Metastatic castration-resistant prostate cancer (mCRPC) is immunologically" cold" and
predominantly resistant to immune checkpoint therapy due to few tumor-infiltrating T cells …

Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …